Chambers Research is conducted by 200 Research Analysts, across 200 jurisdictions and provides nearly 6,000 rankings tables. Annually we collect hundreds of thousands of responses from clients, the majority via in-depth interview. Learn more about our methodology.
This content is provided by Jake Holdreith
Jake Holdreith is a member of the Robins Kaplan Executive Board and leads the firm’s Health and Life Sciences Group. He counsels clients and leads trials of complex lawsuits, including intellectual property, regulatory, antitrust, and constitutional litigation. His cases include pharmaceuticals, medical devices, telecommunications, and electronics.
Mr. Holdreith has delivered multiple trial successes in complex, high-stakes cases, including multi-million dollar verdicts as plaintiff and successful business outcomes and judgments of no liability as defendant. He has experience with matters in the United States, Europe, and Japan. He is an experienced courtroom advocate and trusted business advisor including for pharmaceutical clients in Hatch-Waxman, 505(b)(2), and ANDA matters. He also provides strategic counseling during due diligence and formulation development.
Chambers says Mr. Holdreith "comes recommended for his strengths in high-value IP disputes, particularly in the healthcare and life sciences spaces." His clients attest that he is "very good at developing and communicating strategy" and "acutely aware of business concerns."
Mr. Holdreith is a dual citizen of Germany and the U.S. and speaks fluent German. He provides pro bono immigration legal assistance to asylum seekers. He graduated from the University of Iowa College of Law, J.D. (1990), and from Macalester College, B.A. (1987).